Our results indicate that both the conventional anti-TNF monoclonal antibody treatment and TNF autovaccination are successful in reducing the number and size of lung metastases in this model and supports the use of these agents in clinical trials in patients with metastatic cancer. Here, TNF is linked to metastatic malignant neoplasm.